Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661549 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNATP53TSHRCA1 | |
| SCHEMBL3715777 | 0.79 | CA1 (0.52) | ALDH1A1LMNATP53TSHRCA1 | |
| SCHEMBL496859 | 0.75 | — | — | |
| SCHEMBL5495656 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL10636423 | 0.73 | TSHR (0.39) | LMNATP53TSHRCA1CA9 | |
| SCHEMBL2638214 | 0.73 | TSHR (0.46) | LMNATP53TSHRCA1CA9 | |
| SCHEMBL2423922 | 0.72 | ALDH1A1 (0.46) | ALDH1A1LMNATP53TSHRCA1 | |
| SCHEMBL14125402 | 0.71 | TSHR (0.50) | LMNATP53TSHRCA1CA9 | |
| SCHEMBL16594602 | 0.70 | CA1 (0.32) | CA1CA9 | |
| SCHEMBL787355 | 0.69 | CA1 (0.50) | ALDH1A1LMNATP53TSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120000628-A | Application of 4-methylene glutamic acid in pharmacy | 桂林医学院附属医院 | 2025-05-16 | — | — | CN | disclosed |
| EP-4476355-A1 | PROCESS FOR THE SYNTHESIS OF ALPHA-METHYLENE-GAMMA-BUTYROLACTONE | Henkel AG & Co. KGaA (DE) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023151894-A1 | PROCESS FOR THE SYNTHESIS OF ALPHA-METHYLENE-GAMMA-BUTYROLACTONE | HENKEL AG & CO. KGAA (DE) | 2023-08-17 | — | — | WO | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-8765731-B2 | Benzimidazole analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140142109-A1 | ANTIFOLATE COMBINATIONS | CHELSEA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8658652-B2 | Antifolate combinations | CHELSEA THERAPEUTICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
| US-8354419-B2 | Benzimidazole analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-7951812-B2 | For abnormal cell proliferation, inflammatory diseases, asthma, and arthritis; (S)-N-{4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-methylene-L-glutamic acid disodium salt (CHL1007) | CHELSEA THERAPEUTICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2282740-A1 | ANTIFOLATE COMPOSITIONS | Chelsea Therapeutics, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2011009084-A2 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010120345-A1 | METABOLICALLY INERT ANTIFOLATES: NEW INDICATIONS AND FORMULATIONS | NAIR MADHAVAN G (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100260825-A1 | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches | NAIR MADHAVAN G | 2010-10-14 | — | — | US | disclosed |
| EP-2125818-A1 | NEW CLASSICAL ANTIFOLATES | Chelsea Therapeutics, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009126637-A1 | ANTIFOLATE COMPOSITIONS | CHELSEA THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253720-A1 | ANTIFOLATE COMPOSITIONS | CHELSEA THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008089390-A1 | NEW CLASSICAL ANTIFOLATES | CHELSEA THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142109-A1 | ANTIFOLATE COMBINATIONS | DHFR, MTX1, MTHFD1 | ALDH1A1 316/4885LMNA 4507/4885TP53 1958/4885 |
| US-20080214585-A1 | NEW CLASSICAL ANTIFOLATES | FFAR3, CCR9, NR1H3 | ALDH1A1 2403/4885LMNA 2605/4885TP53 4066/4885 |
| US-20100260825-A1 | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches | SLC19A1, TPMT, DHFR | ALDH1A1 851/4885LMNA 4574/4885TP53 1222/4885 |
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | ALDH1A1 969/4885LMNA 797/4885TP53 3082/4885 |
| US-20090253720-A1 | ANTIFOLATE COMPOSITIONS | FDFT1, SLC19A1, FIBP | ALDH1A1 1831/4885LMNA 4714/4885TP53 1941/4885 |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | ALDH1A1 969/4885LMNA 797/4885TP53 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.